StockNews.com Lowers LeMaitre Vascular (NASDAQ:LMAT) to Hold

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

A number of other research analysts also recently issued reports on LMAT. JMP Securities boosted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Roth Mkm reissued a “buy” rating and set a $100.00 price target on shares of LeMaitre Vascular in a report on Friday, May 31st. Barrington Research lifted their price objective on shares of LeMaitre Vascular from $79.00 to $92.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. Finally, Roth Capital upgraded LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and a consensus target price of $90.33.

LeMaitre Vascular Trading Down 1.0 %

Shares of LMAT stock traded down $0.90 during mid-day trading on Tuesday, reaching $89.86. The stock had a trading volume of 76,805 shares, compared to its average volume of 127,162. LeMaitre Vascular has a 1-year low of $44.27 and a 1-year high of $92.90. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of 59.51, a PEG ratio of 2.63 and a beta of 0.89. The business’s fifty day moving average is $84.58 and its 200-day moving average is $75.01.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.63%. The company had revenue of $55.85 million for the quarter, compared to the consensus estimate of $54.98 million. During the same quarter in the prior year, the company earned $0.37 EPS. LeMaitre Vascular’s quarterly revenue was up 11.4% on a year-over-year basis. On average, analysts forecast that LeMaitre Vascular will post 1.77 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the sale, the chief executive officer now directly owns 1,958,328 shares in the company, valued at $168,944,956.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO George W. Lemaitre sold 27,030 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the transaction, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The disclosure for this sale can be found here. Insiders have sold 43,251 shares of company stock valued at $3,714,994 in the last ninety days. 10.79% of the stock is currently owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

Institutional investors have recently made changes to their positions in the company. YHB Investment Advisors Inc. purchased a new position in LeMaitre Vascular in the first quarter worth approximately $36,000. GAMMA Investing LLC grew its holdings in shares of LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 199 shares during the period. SRS Capital Advisors Inc. increased its position in shares of LeMaitre Vascular by 325.5% during the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 524 shares during the last quarter. West Oak Capital LLC acquired a new stake in shares of LeMaitre Vascular during the 2nd quarter worth about $58,000. Finally, nVerses Capital LLC raised its holdings in LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.